Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces a selection of new contract wins where Optimer technology is being…
28/11/2022 Baroness Susan Greenfield opened the new site and presented on the challenges in scientific discovery Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in…
Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…
DNA day on April 25th, celebrates major scientific achievements concerning DNA, in particular the completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix…
As SARS-CoV-2 continues to mutate we demonstrate the performance of
04/04/2022 Aptamer Group’s CEO, Dr Arron Tolley, has been awarded a Visiting Professorship in Biological and Translational Sciences from the Faculty of Health and Medical Sciences, University of Surrey, in…
14/10/2021 Selected as the preferred aptamer partner to support high-throughput development of affinity binding reagents for proteomics research Contract comprises upfront payment and potential for…
Last week the government released their new Life Sciences Vision. This 10-year strategy for the sector aims to ensure that the United Kingdom builds a supportive environment for…
April 25th is DNA day. This day celebrates the completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix in 1953. DNA aptamers are cheaper…
Anti-hapten antibodies are difficult and slow to generate limiting cheap and efficient bioanalysis in this field. Our proprietary methods offer standard assay formats, such as ELISA and lateral flow…
